Cargando…
Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease
BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors represent a promising class of lipid‐lowering therapy, although their use has been limited by cost concerns. METHODS AND RESULTS: A retrospective cohort study was conducted using a nationwide commercial claims database comp...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200752/ https://www.ncbi.nlm.nih.gov/pubmed/33904340 http://dx.doi.org/10.1161/JAHA.120.019331 |